Pulmonary vascular disease in Gaucher disease: Clinical spectrum, determinants of phenotype and long-term outcomes of therapy

Journal of Inherited Metabolic Disease

Volumn 34, Issue 3, 2011, Pages 643-650

  Lo, Sarah Michelman ^a   Liu, Jun ^a   Chen, F ^a   Pastores, G M ^b   Knowles, J ^c   Boxer, M ^d   Aleck, Kirk ^e   Mistry, Pramod K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d US Oncology   (United States)

^e ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ASPARAGINE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; IMIGLUCERASE; PROSTACYCLIN; SERINE; SILDENAFIL;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATOPULMONARY SYNDROME; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; PHENOTYPE; PULMONARY HYPERTENSION; SCORING SYSTEM; SEVERITY SCORE INDEX; SEX RATIO; SPLENECTOMY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GAUCHER DISEASE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHENOTYPE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959798635     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9313-9     Document Type: Article

References (33)

1. Austin ED, Loyd JE (2007) Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med 28(1):43-57, vii-viii
2. Choi M, Scholl UI, Ji W et al. (2009) Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 106(45):19096-19101
3. Cox TM, Aerts JM, Belmatoug N et al. (2008) Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 31(3):319-36, Epub 2008 May 23. Review
4. Dawson A, Elias DJ, Rubenson D et al. (1996) Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann Intern Med 125(11):901-904
5. Elleder M (2006) Glucosylceramide transfer from lysosomes - the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis 29(6):707-715
6. Elstein D, Klutstein MW, Lahad A et al. (1998) Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet 351:1544-1546 (Pubitemid 28230889)
7. Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372(9645):1263-1271
8. Grabowski GA, Kolodyny EH, Weinreb NJ, et al. (2006) Gaucher disease: phenotypic and genetic variation. In: Schriver CR, Beaudet AL, Sly WS, et al. (eds.) The Online Metabolic and Molecular Basis of Inherited Diseases (ww.ommbid.com). McGraw-Hill, New York, Ch 146.1
9. Hůlková H, Poupetová H, Harzer K et al. (2010) Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries. J Inherit Metab Dis 33(1):69-78
10. Humbert M, Morrell N, Archer S et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):13S-24S
11. Lachmann RH, Wight DG, Lomas DJ et al. (2000) Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 93(4):237-244 (Pubitemid 30198961)
12. Lee RE, Yousem SA (1988) The frequency and type of lung involvement in patients with Gaucher's disease. Lab Invest 58:54A
13. Lee S, Shroyer K, Markham N, Cool C, Voelkel N, Tuder R (1998) Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101:927-934 (Pubitemid 28125268)
14. Lo SM, Stein P, Mullaly S et al. (2010) Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types-correlation with genotype and phenotype. Am J Hematol 85(5):340-5
15. Loyd JE, Atkinson JB, Pietra GG et al. (1988) Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis 138(4):952-957
16. Loyd JE, Butler MD, Foroud TM et al. (1998) Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 152:93-97
17. Mistry PK, Wraight EP, Cox TM (1996) Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 348(9041):1555-1559 (Pubitemid 26411655)
18. Mistry PK, Sirrs S, Chan A et al. (2002) Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77:91-98 (Pubitemid 35189608)
19. Mistry PK, Cappellini MD, Lukina E et al. (2010) A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol
20. Mistry PK, Liu J, Yang M et al. (2010b) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA 107(45):19473-19478
21. Möller T, Leren TP, Eiklid KL et al. (2010) A novel BMPR2 gene mutation associated with exercise-induced pulmonary hypertension in septal defects. Scand Cardiovasc J 44(6):331-336
22. Morse JH (2002) Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension. Chest 121(3 Suppl):50S-53S
23. Newman JH, Phillips JA 3rd, Loyd JE (2008) Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med 148(4):278-283 (Pubitemid 351665488)
24. Roberts WC, Fredrickson DS (1967) Gaucher's disease of the lung causing severe pulmonary hypertension with associated acute recurrent pericarditis. Circulation 35:783-789
25. Rodriguez-Roisin R, Krowka MJ (1994) Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. Eur Respir J 7:839-842 (Pubitemid 24153579)
26. Ross DJ, Spira S, Buchbinder NA (1997) Gaucher Cells in pulmonary-capillary blood in association with pulmonary hypertension. N Engl J Med 336:379-381 (Pubitemid 27057196)
27. Smith RL, Hutchins GM, Sack GH Jr, Ridolfi RL (1978) Unusual cardiac, renal and pulmonary involvement in Gaucher's disease. Interstitial glucocerebroside accumulation, pulmonary hypertension and fatal bone marrow embolization. Am J Med 65:352-360 (Pubitemid 8387975)
28. Taddei TH, Kacena KA, Yang M et al. (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk. Am J Hematol 84(4):208-214
29. Tayebi N, Cushner S, Sidransky E (1996) Differentiation of the glucocerebrosidase gene from pseudogene by long-template PCR: implications for Gaucher disease. Am J Hum Genet 59:740-741 (Pubitemid 26269055)
30. Thachil J (2009) The enigma of pulmonary hypertension after splenectomy - does the megakaryocyte provide a clue? QJM 102(10):743-5, Epub 2009 Jul 21
31. Theise ND, Ursell PC (1990) Pulmonary hypertension and Gaucher's disease: logical association or mere coincidence? Am J Pediatr Hematol Oncol 12:74-76
32. Yeager M, Halley G, Golpon H, Voelkel N, Tuder R (2001) Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 88:E2-E11
33. Zimran A, Kay A, Gelbart T et al. (1992) Gaucher disease: clinical, laboratory radiologic and genetic features of 53 patients. Medicine 71:337-353